ILF With/Without Cisplatin for Advanced Gastric Cancer

• Status: Unknown status
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Treatments: Cisplatin; Irinotecan

Criteria

Inclusion Criteria:

• Histologically proven gastric adenocarcinoma

• Advanced, metastatic or recurrent

• ECOG performance status 0 to 2

• No prior chemotherapy

• Measurable or evaluable indicator lesion(s)

• Normal marrow, hepatic and renal functions

• Provision of written informed consent

Exclusion Criteria:

• Active infection, bleeding or severe comorbidities

• Pregnant or breastfed women

• Active CNS metastasis